Soner AKÇİN, Mürsel DAVARCI, Ahmet GÖKÇE, Eşref Oğuz GÜVEN, Mehmet İNCİ, Fatih Rüştü YALÇINKAYA, Mevlana Derya BALBAY

Urodynamic evaluation of acute effects of sildenafi l on voiding among males with erectile dysfunction and symptomatic benign prostate

Aim: To evaluate the acute eff ects of sildenafi l citrate on micturition of men with erectile dysfunction and symptomatic benign prostatic hyperplasia using urodynamic parameters. Materials and methods: Between June and December 2009, a total of 50 patients over the age of 40 participated in the study. Th e patients were admitted to our hospital with erectile dysfunction and moderate to severe lower urinary symptoms with benign prostatic hyperplasia. To examine the sexual function of the participants, we used the IIEF-5 Sexual Health Inventory for Men questionnaire. Patients were randomly divided into 2 groups: a treatment group and a control group. A basal urodynamic evaluation was performed in both groups. Aft er the urodynamic evaluation, 50 mg of sildenafi l was given to the patients in the control group and 1 h later a second evaluation was performed. Following the urodynamic evaluation, a placebo was given to the patients in the control group and then a second evaluation was performed aft er 1 h. Results: A statistically signifi cant increase was seen in maximal fl ow and average fl ow (Qmax and Qave) aft er 1 hin the treatment group. Th e increase in the control group was not signifi cant. Conclusion: Based on the study fi ndings, we suggest that sildenafi l has an eff ect on micturition in the short term. However, to determine the role of sildenafil in the treatment of BPH/LUTS, further studies with larger patient groups are needed.

PDF

___

1. Yalçınkaya FR, Gökçe A, Davarcı M, Güven EO, İnci M, Kartal SB et al. Th e impact of NIH-IV prostatitis on early post-operative outcomes of the impact of NIH-IV prostatitis on early postoperative outcomes of transurethral resection of the prostate in patients with symptomatic benign prostate hyperplasia. Turk J Med Sci 2011; 41: 515-519.
2. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 7: 270: 83-90.
3. Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 2004; 84: 935-86.
4. Gacci M, Bartoletti R, Figlioli S, Sarti E, Eisner B, Boddi V et al. Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and aft er prostatectomy: a prospective study. BJU Int 2003; 91: 196-200.
5. Blanker MH, Bohnen AM, Groeneveld FP, Bernsen RM, Prins A, Thomas S et al. Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study. J Am Geriatr Soc 2001; 49: 436-42.
6. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int 2002; 90: 836-39.
7. Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006; 3: 662-667.
8. Rostaing L, Tran-Van T, Ader JL. Increased glomerular fi ltration rate in kidney-transplant recipients who take sildenafi l. N Engl J Med 2000; 342: 1679-80.
9. Tinel H, Stelte-Ludwig B, Hutter J, Sandner P. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006; 98: 1259-63.
10. Uckert S, Kuthe A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001; 166: 2484-90.
11. Guven EO, Balbay MD, Mete K, Serefoglu EC. Urofl owmetric assessment of acute eff ects of sildenafi l on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia. Int Urol Nephrol 2009; 41: 287-92.
12. Kojima M, Inui E, Ochiai A, Naya Y, Ukimura O, Watanabe H. Noninvasive quantitative estimation of infravesical obstruction using ultrasonic measurement of bladder weight. J Urol 1997; 157: 476-9.
13. Davis-Joseph B, Tiefer L, Melman A. Accuracy of the initial history and physical examination to establish the etiology of erectile dysfunction. Urology 1995; 45: 498-502.
14. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
15. Chang S, Hypolite JA, Zderic SA, Wein AJ, Chacko S, DiSanto ME. Enhanced force generation by corpus cavernosum smooth muscle in rabbits with partial bladder outlet obstruction. J Urol 2002; 167: 2636-44.
16. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007; 148: 1019-29.
17. Lue TF. Erectile dysfunction. N Engl J Med 2000; 342: 1802-13.
18. Gülkesen KH, Köksal IT, Özdem S, Saka O. Prediction of prostate cancer using decision tree algorithm. Turk J Med Sci 2010; 40: 681-686.
19. Doğan H, Canbaz S, Tander B, Pekşen Y, Cantürk F, Oruç NO. Th e prevalence of home injuries among elderly people in Samsun, Turkey, and the infl uencing factors. Turk J Med Sci 2010; 40: 651- 658.
20. Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J et al. EAU Guidelines on erectile dysfunction: an update. Eur Urol 2006; 49: 806-15.
21. Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H. Eff ects of nitric oxide on human and canine prostates. Urology 1995; 45: 440-6.
22. Avcı A, Atlı T, Ergüder BI, Varlı M, Devrim E, Demir O et al. Eff ects of grape consumption on plasma and erythrocyte antioxidant parameters in elderly subjects. Turk J Med Sci 2010; 40: 525-529.
23. Cook AL, Haynes JM. Protein kinase G II-mediated proliferative effects in human cultured prostatic stromal cells. Cell Signal 2004; 16: 253-61.
24. Gökçe A, Aslan S, Yalçınkaya FR, Davarcı M, Kaya YS, Savaş N et al. Improvement of monosymptomatic enuresis aft er adenotonsillectomy in children with obstructive sleep apnea syndrome. Turk J Med Sci 2012; 42: 757-761.
25. Dokita S, Morgan WR, Wheeler MA, Yoshida M, Latifpour J, Weiss RM. NG-nitro-L-arginine inhibits non-adrenergic, noncholinergic relaxation in rabbit urethral smooth muscle. Life Sci 1991; 48: 2429-36.
26. Adolfsson PI, Ahlstrand C, Varenhorst E, Svensson SP. Lysophosphatidic acid stimulates proliferation of cultured smooth muscle cells from human BPH tissue: sildenafi l and papaverin generate inhibition. Prostate 2002; 51: 50-58.
27. Qiu Y, Kraft P, Craig EC, Liu X, Haynes-Johnson D. Cyclic nucleotide phosphodiesterases in rabbit detrusor smooth muscle. Urology 2002; 59: 145-49.
28. AL-Nımer MS, AL-Obaıdı SA, AL-Dulaımı KS. Serum nitric oxide and peroxynitrite levels in adult sero-positive rheumatoid arthritis treated with disease modifying antirheumatic drugs: a preliminary report. Turk J Med Sci 2010; 40: 191-197.
29. Yeni E, Cift ci H, Savas M, Verit A, Taşkın A. Is oxidative stress an etiologic factor in idiopathic male infertility? Turk J Med Sci 2010; 40: 1-6.
30. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007; 51: 1717-23.
31. Gingell C, Sultana SR, Wulff MB, Gepi-Attee S. Duration of action of sildenafil citrate in men with erectile dysfunction. J Sex Med 2004; 1: 179-84.
32. Guler C, Tuzel E, Dogantekin E, Kiziltepe G. Does sildenafi l aff ect urofl owmetry values in men with lower urinary tract symptoms suggestive of benign prostatic enlargement? Urol Int 2008; 80: 181- 5.
33. Gümüş D, Bağdatlı Y. A bacteriological examination of urine before and after urodynamic testing. Turk J Med Sci 2010; 40: 317- 322.